Clinical Trials Logo

brca2 Mutation Carrier clinical trials

View clinical trials related to brca2 Mutation Carrier.

Filter by:

NCT ID: NCT02314156 Completed - Clinical trials for Stage IB Breast Cancer

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy). Telapristone acetate may help prevent breast cancer from forming in premenopausal women. Giving telapristone acetate transdermally may be safer and have fewer side effects than oral administration.

NCT ID: NCT02208375 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Start date: November 11, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Olaparib, vistusertib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01905046 Active, not recruiting - Clinical trials for Ductal Breast Carcinoma in Situ

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Start date: November 23, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent breast cancer.

NCT ID: NCT01874184 Completed - Clinical trials for Ductal Breast Carcinoma in Situ

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer

DEEM
Start date: October 2013
Phase: N/A
Study type: Interventional

This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer. Studying the effects that changes to daily eating and exercise habits can have on the body's hormone levels and the body's ability to activate proteins may help doctors identify interventions for individuals at high risk for breast cancer.

NCT ID: NCT01540565 Completed - Clinical trials for Recurrent Ovarian Carcinoma

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: April 9, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well veliparib works in treating patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back or does not respond to treatment. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01233505 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with capecitabine and oxaliplatin may kill more tumor cells.

NCT ID: NCT01219075 Completed - Clinical trials for Stage IIIA Breast Cancer

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Start date: July 1, 2010
Phase: N/A
Study type: Interventional

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer. PURPOSE: This clinical trial studies soy isoflavones supplementation in treating women at high risk for or with breast cancer.

NCT ID: NCT01154426 Completed - Clinical trials for Adult Solid Neoplasm

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of giving ABT-888 together with gemcitabine hydrochloride in treating patients with advanced solid tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with gemcitabine hydrochloride may kill more tumor cells.

NCT ID: NCT01097278 Completed - Breast Cancer Clinical Trials

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Start date: November 1, 2011
Phase: N/A
Study type: Interventional

RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women.

NCT ID: NCT00986206 Completed - Ovarian Cancer Clinical Trials

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

Start date: June 2009
Phase: N/A
Study type: Observational

RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer. PURPOSE: This clinical trial is studying using the lysophosphatidic acid assay to see how well it works in early detection of ovarian cancer in patients with ovarian cancer or who are at risk for ovarian cancer.